

MEA Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 334 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

Middle East and Africa Kidney Cancer Diagnostics Market is projected to register a CAGR of 4.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Middle East and Africa Kidney Cancer Diagnostics Market, By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stages (Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, and Non-Clear Cell Renal Cell Carcinoma), Product (Platform-Based Products, Instrument based products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel, and the Rest of Middle East and Africa), Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the kidney cancer diagnostics market are:

- Rising healthcare expenditure for better health services
- Growing demand for better quality healthcare
- Growing prevalence of kidney cancer

Market Players

Some of the key market players for Middle East and Africa kidney cancer diagnostics market are listed below:

- BD
- BioVendor R&D
- Canon Medical Systems Corporation
- CENTOGENE N.V.
- FUJIFILM Corporation
- GeneDx,LLC

Scotts International, EU Vat number: PL 6772247784

- Illumina, Inc.
- Invitae Corporation
- Koninklijke Philips N.V.
- Laboratory Corporation of America Holdings
- Myriad Genetics, Inc.
- Qiagen
- Seimens Healthcare GmbH
- Thermo Fisher Scientific Inc.

Table of Contents:

TABLE OF CONTENTS

- 1 INTRODUCTION 84
- 1.1 OBJECTIVES OF THE STUDY 84
- 1.2 MARKET DEFINITION 84
- 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET 84
- 1.4 CURRENCY AND PRICING 86
- 1.5 LIMITATIONS 87
- 1.6 MARKETS COVERED 87
- 2 MARKET SEGMENTATION 91
- 2.1 MARKETS COVERED 91
- 2.2 GEOGRAPHICAL SCOPE 92
- 2.3 YEARS CONSIDERED FOR THE STUDY 93
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 94
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
- 2.6 MULTIVARIATE MODELLING 98
- 2.7 MARKET APPLICATION COVERAGE GRID 99
- 2.8 TEST TYPE LIFELINE CURVE 100
- 2.9 DBMR MARKET POSITION GRID 101
- 2.10 VENDOR SHARE ANALYSIS 102
- 2.11 SECONDARY SOURCES 103
- 2.12 ASSUMPTIONS 103
- 3 EXECUTIVE SUMMARY 104
- 4 PREMIUM INSIGHTS 107
- 4.1 PESTEL ANALYSIS 108
- 4.2 PORTER'S 5 FORCES 109
- 4.3 EPIDEMIOLOGY 110
- 4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 111
- 4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 111
- **5 INDUSTRY INSIGHTS 112**
- 6 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 114

Page 2/8

- 7 MARKET OVERVIEW 117
- 7.1 DRIVERS 119
- 7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 119
- 7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 121

Scotts International. EU Vat number: PL 6772247784

- 7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 122
- 7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 122
- 7.2 RESTRAINTS 123
- 7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 123
- 7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 124
- 7.3 OPPORTUNITIES 124
- 7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 124
- 7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 125
- 7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 125
- 7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 126
- 7.4 CHALLENGES 126
- 7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 126
- 7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 127
- 8 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 128
- **8.1 OVERVIEW 129**
- 8.2 IMAGING 133
- 8.2.1 COMPUTED TOMOGRAPHY 134
- 8.2.2 ULTRASOUND 134
- 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 134
- 8.2.4 ANGIOGRAPHY 134
- 8.2.5 X-RAY 134
- 8.2.6 OTHERS 134
- 8.3 BLOOD TEST 134
- 8.4 BIOPSY 135
- 8.4.1 FINE NEEDLE ASPIRATION 136
- 8.4.2 NEEDLE CORE BIOPSY 136
- 8.5 BIOMARKER TEST 136
- 8.5.1 AQUAPORIN 1 (AQP1) 138
- 8.5.2 PERILIPIN (PLIN2) 138
- 8.5.3 N-METHYLTRANSFERASE (NMNT) 138
- 8.5.4 L-PLASTIN (LCP-1) 138
- 8.5.5 NM23A 138
- 8.6 GENETIC TEST 138
- 8.7 OTHERS 139
- 9 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 141
- 9.1 OVERVIEW 142
- 9.2 STAGE I 145
- 9.3 STAGE II 145
- 9.4 STAGE III 146
- 9.5 STAGE IV 147
- 10 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 148
- 10.1 OVERVIEW 149
- 10.2 RENAL CELL CARCINOMA 153
- 10.2.1 IMAGING 154
- 10.2.2 BLOOD TEST 154
- 10.2.3 BIOPSY 154

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 10.2.4 BIOMARKER TEST 154
- 10.2.5 GENETIC TEST 154
- 10.2.6 OTHERS 154
- 10.3 CLEAR CELL RENAL CELL CARCINOMA 154
- 10.3.1 IMAGING 156
- 10.3.2 BLOOD TEST 156
- 10.3.3 BIOPSY 156
- 10.3.4 BIOMARKER TEST 156
- 10.3.5 GENETIC TEST 156
- 10.3.6 OTHERS 156
- 10.4 NON CLEAR CELL RENAL CELL CARCINOMA 156
- 10.4.1 PAPILLARY RENAL CELL CARCINOMA 157
- 10.4.1.1 IMAGING 158
- 10.4.1.2 BLOOD TEST 158
- 10.4.1.3 BIOPSY 158
- 10.4.1.4 BIOMARKER TEST 158
- 10.4.1.5 GENETIC TEST 158
- 10.4.1.6 OTHERS 158
- 10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 158
- 10.4.2.1 IMAGING 159
- 10.4.2.2 BLOOD TEST 159
- 10.4.2.3 BIOPSY 159
- 10.4.2.4 BIOMARKER TEST 159
- 10.4.2.5 GENETIC TEST 159
- 10.4.2.6 OTHERS 159
- 11 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 160
- 11.1 OVERVIEW 161
- 11.2 INSTRUMENT BASED PRODUCTS 165
- 11.2.1 IMAGING 166
- 11.2.2 BIOPSY 166
- 11.3 PLATFORM BASED PRODUCTS 166
- 11.3.1 NEXT GENERATION SEQUENCING 168
- 11.3.2 MICROARRAYS 168
- 11.3.3 PCR 169
- 11.3.4 OTHERS 169
- 11.4 KITS AND REAGENTS 169
- 11.4.1 RENAL CANCER PANELS 171
- 11.4.2 RENAL CANCER ANTIBODIES 171
- 11.5 OTHER CONSUMABLES 171
- 12 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 172
- 12.1 OVERVIEW 173
- 12.2 FLUORESCENT IN SITU HYBRIDIZATION 176
- 12.3 NEXT GENERATION SEQUENCING 176
- 12.4 FLUORIMMUNOASSAY 177
- 12.5 COMPARATIVE GENOMIC HYBRIDIZATION 178
- 12.6 IMMUNOHISTOCHEMICAL 179
- 12.7 OTHERS 179

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 181
- 13.1 OVERVIEW 182
- 13.2 SCREENING 185
- 13.2.1 INSTRUMENT BASED PRODUCTS 186
- 13.2.2 PLATFORM BASED PRODUCTS 186
- 13.2.3 KITS AND REAGENTS 186
- 13.2.4 OTHER CONSUMABLES 186
- 13.3 DIAGNOSTIC AND PREDICTIVE 186
- 13.3.1 INSTRUMENT BASED PRODUCTS 187
- 13.3.2 PLATFORM BASED PRODUCTS 187
- 13.3.3 KITS AND REAGENTS 187
- 13.3.4 OTHER CONSUMABLES 187
- 13.4 PROGNOSTIC 188
- 13.4.1 INSTRUMENT BASED PRODUCTS 189
- 13.4.2 PLATFORM BASED PRODUCTS 189
- 13.4.3 KITS AND REAGENTS 189
- 13.4.4 OTHER CONSUMABLES 189
- 13.5 RESEARCH 189
- 13.5.1 INSTRUMENT BASED PRODUCTS 190
- 13.5.2 PLATFORM BASED PRODUCTS 190
- 13.5.3 KITS AND REAGENTS 190
- 13.5.4 OTHER CONSUMABLES 191
- 14 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 192
- 14.1 OVERVIEW 193
- **14.2 HOSPITALS 196**
- 14.3 DIAGNOSTIC CENTERS 196
- 14.4 CANCER RESEARCH CENTERS 197
- 14.5 ACADEMIC INSTITUTES 198
- 14.6 AMBULATORY SURGICAL CENTERS 198
- 14.7 OTHERS 199
- 15 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 200
- 15.1 OVERVIEW 201
- 15.2 DIRECT TENDER 204
- 15.3 RETAIL SALES 204
- 15.4 OTHERS 205
- 16 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 206
- 16.1 MIDDLE EAST AND AFRICA 207
- 16.1.1 SOUTH AFRICA 220
- 16.1.2 SAUDI ARABIA 227
- 16.1.3 BAHRAIN 235
- 16.1.4 U.A.E. 242
- 16.1.5 EGYPT 250
- 16.1.6 ISRAEL 258
- 16.1.7 KUWAIT 266
- 16.1.8 OMAN 274
- 16.1.9 QATAR 282
- 16.1.10 REST OF MIDDLE EAST AND AFRICA 290

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 291
- 17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 291
- 18 SWOT ANALYSIS 292
- 19 COMPANY PROFILE 293
- 19.1 CANON MEDICAL SYSTEMS CORPORATION 293
- 19.1.1 COMPANY SNAPSHOT 293
- 19.1.2 REVENUE ANALYSIS 293
- 19.1.3 COMPANY PROFILE 294
- 19.1.4 PRODUCT PORTFOLIO 294
- 19.1.5 RECENT DEVELOPMENT 294
- 19.2 KONINKLIJKE PHILIPS N.V. 295
- 19.2.1 COMPANY SNAPSHOT 295
- 19.2.2 REVENUE ANALYSIS 295
- 19.2.3 COMPANY PROFILE 296
- 19.2.4 PRODUCT PORTFOLIO 296
- 19.2.5 RECENT DEVELOPMENTS 297
- 19.3 GENERAL ELECTRIC COMPANY 298
- 19.3.1 COMPANY SNAPSHOT 298
- 19.3.2 REVENUE ANALYSIS 298
- 19.3.3 COMPANY PROFILE 299
- 19.3.4 PRODUCT PORTFOLIO 299
- 19.3.5 RECENT DEVELOPMENTS 300
- 19.4 SIEMENS HEALTHCARE GMBH 301
- 19.4.1 COMPANY SNAPSHOT 301
- 19.4.2 REVENUE ANALYSIS 301
- 19.4.3 COMPANY PROFILE 302
- 19.4.4 PRODUCT PORTFOLIO 302
- 19.4.5 RECENT DEVELOPMENT 303
- 19.5 GRAIL 304
- 19.5.1 COMPANY SNAPSHOT 304
- 19.5.2 PRODUCT PORTFOLIO 304
- 19.5.3 RECENT DEVELOPMENTS 304
- 19.6 AMBRY GENETICS 306
- 19.6.1 COMPANY SNAPSHOT 306
- 19.6.2 PRODUCT PORTFOLIO 306
- 19.6.3 RECENT DEVELOPMENT 306
- 19.7 BIOVENDOR R&D 307
- 19.7.1 COMPANY SNAPSHOT 307
- 19.7.2 PRODUCT PORTFOLIO 307
- 19.7.3 RECENT DEVELOPMENT 307
- 19.8 BLUEPRINT GENETICS OY. 308
- 19.8.1 COMPANY SNAPSHOT 308
- 19.8.2 PRODUCT PORTFOLIO 308
- 19.8.3 RECENT DEVELOPMENT 308
- 19.9 CD GENOMICS 309
- 19.9.1 COMPANY SNAPSHOT 309
- 19.9.2 PRODUCT PORTFOLIO 309

19.9.3 RECENT DEVELOPMENT 309

19.10 CENTOGENE N.V. 310

19.10.1 COMPANY SNAPSHOT 310

19.10.2 REVENUE ANALYSIS 310

19.10.3 PRODUCT PORTFOLIO 311

19.10.4 RECENT DEVELOPMENT 311

19.11 CREATIVE DIAGNOSTICS 312

19.11.1 COMPANY SNAPSHOT 312

19.11.2 PRODUCT PORTFOLIO 312

19.11.3 RECENT DEVELOPMENT 312

19.12 FUJIFILM CORPORATION 313

19.12.1 COMPANY SNAPSHOT 313

19.12.2 REVENUE ANALYSIS 313

19.12.3 PRODUCT PORTFOLIO 314

19.12.4 RECENT DEVELOPMENTS 314



Print this form

To place an Order with Scotts International:

MEA Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 334 pages | Data Bridge Market Research

☐ - Complete the rele	evant blank fields and sign			
 Send as a scanned email to support@scotts-international.com 				
ORDER FORM:				
Select license	License			Price
	Single User License			\$3500.00
	Corporate Users License			\$4200.00
VAT				
			Total	
*Please circle the relevan	t license ontion. For any questions please	contact support@sco	atts-international com or 0048 603 3	94 346
*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. [** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Number				
_ vvi viii se adaea ac	25 / 0 To To Histi Basea companies, marviado	ais and Lo basea com	paines who are unable to provide a	vana 20 vac ramber
Email*		Phone*		
First Name*		Last Name*		
Job title*				
Company Name*		EU Vat / Tax ID / NII	P number*	
Address*		City*		
Zip Code*		Country*		
		Date	2025-05-07	
		Signature		
		Signature		